World Journal of Pharmaceutical Sciences
ISSN (Print): 2321-3310; ISSN (Online): 2321-3086
Available online at: https://wjpsonline.com/
Review Article

Review on Tissue Engineering: Recent Advances and Future Prospects

[2]Dr.Y.Sirisha, [3]B.Thangabalan, [1*]Kosuri Avinash Goud, [4]Jampani Venkata Ravindra Kumar, [4]Ganji Srujini, [5]Sujata Sasmal, [5]Oinam Indikas Singh, [6]Mora Vyshnavi, [6]Shake Farid Uddin.

[3]Principal and Professor, Department of Pharmaceutical Analysis, SIMS College of Pharmacy, Mangaladas Nagar, Guntur.
[2]Professor & Research Guide, Pharmaceutical Analysis, Sims college of pharmacy, Guntur.
[1,4,5,6] IV/IV-B.Pharmacy Student, Sims college of pharmacy, Guntur.

Received: 02-03-2026 / Revised Accepted: 07-03-2026 / Published: 17-03-2026

ABSTRACT:

Tissue engineering is fast developing out of both a conceptual framework to a transitional field encompassing biomaterials, stem cells, bioprinting technologies, and regenerative therapies. In the past several years, impressive innovations in scaffolding structure, new biofabrication techniques, vascularisation approaches, and exosome-based approaches have challenged the limits to what can be manufactured and regenerated. This review article is a thorough review of the current developments in tissue engineering in the recent past, the challenges and future aspects of tissue engineering. Understanding biomaterials, 3D bioprinting advancements, stem cell uses, vascularization, and innervation plans, regulatory, and commercialization are discussed. Last but not least, it gives realistic predictions to the field within the coming decade, which is scalable manufacturing, immune-instructive materials, and harmonizing regulation.

KEY WORDS: Tissue engineering, biomaterials, 3D bioprinting, vascularization, exosomes, regenerative medicine, translational research.

INTRODUCTION

Tissue engineering (TE) is a bioscientific field of urgent convergence of cell biology, materials science, and bioengineering, focused on the production or replacement of damaged tissues. Conceived originally as a theoretical discipline, TE has in recent years obtained a point at which preclinical achievements are beginning to have most of the early-stage clinical solutions. Its effect is in various fields, such as orthopaedics, cardiovascular repair, dermatology, and organ regeneration. Current efforts have concerned enhancing biocompatibility of the scaffold and optimization of cellual response, functional vascularization, and incorporated high-tech manufacturing approaches that include 3D bioprinting and organ-on-chip cultures.

In spite of these advances, TE continues to have issues relating to scaling up constructs to the complexity of organs, regulation of immune reactions, standardization of cell-based treatments and conforming to in vivo regulatory mechanisms. These dynamics are key to be understood in order to facilitate bench-to-bedside translation.

2. Design of Biomaterials and Scaffolds.

2.1. The Development of Scaffold Materials.

The scaffolds create the physical structure onto which cells get attached, expand and differentiate. Initial scaffold designs were relatively inert though, recent research has seen the production of highly bioactive, customisable and intelligent biomaterials. Natural polymers like collagen, gelatins, hyaluronic acid and alginate are highly-biocompatible yet do not possess mechanical strength. Artificial polymers such as PLGA, PEG, and PCL do have tunable properties, but need to be surface modified in order to promote cell attachment.

Address for Correspondence: Kosuri Avinash Goud, IV/IV-B.Pharmacy Student, Sims college of pharmacy, Guntur, Mail: kosuriavinashgoud@gmail.com.

How to Cite this Article: Kosuri Avinash Goud, Review on Tissue Engineering: Recent Advances and Future Prospects, World J Pharm Sci 2026; 14(01): 6-9; https://doi.org/10.54037/WJPS.2022.100905

Nowadays hybrid biomaterials combining the merits of natural scaffolds and synthetic ones are produced in a large number. Decellularized ECM- based scaffolds are close to natural tissue microenvironments and are utilized more frequently in soft tissue engineering.

2.2. Biomaterials, Smart and Functional.

The next major innovation in scaffold manufacturing has been the incorporation of smart materials that react to environmental cues (pH, temperature, or mechanical stress) into the scaffold. These materials are able to emit drugs or growth factors as required increasing the efficiency of healing. Nanocomposite scaffold with ceramics, metallic nanoparticles or bioactive molecules have been used to enhance mechanical integrity and bioactivity especially in bone tissue engineering. Scaffolds made by plants are also of interest because they are relatively cheap and natural porosity is a characteristic of natural materials.

3. The Tissue Engineering Components of cells.

3.1. Differentiation and Stem Cells.

The regenerative and immunomodulatory characteristics of Mesenchymal stem cells (MSCs) have remained one of the cornerstones of TE. Induced pluripotent stem cells (iPSCs) offer patient-specific cells with differentiable abilities, which have the capability to be differentiated into various lineages previously unattainable. The therapeutic efficacy of these cells is continued to get better through genetic engineering techniques.

3.2. Exosome-Based Therapies

In the recent past cell-free therapies have come into the limelight as an effective substitute to the conventional cell transplants. Signaling molecules found in exosomes (secreted extracellular vesicles) by stem cells facilitate tissue regeneration without the dangers of live cells, including tumorigenicity or immunogenicity (Muel 2007). Controlled and localized release can be delivered via exosome-laden scaffolds or hydrogels and has shown good promise in repairing bones, skin, and nerves.

4. Progress in 3D Bioprinting and Bio fabrication.

TE has become revolutionized with the introduction of 3D bioprinting that supports a precise spatial arrangement of cells and biomaterials to achieve a complex tissue architecture. The most recent ones are multi material printing, high-resolution nozzle systems, and sacrificial bioinks to produce perfusable vascular networks. Bioinks that are hybrid with a blend of natural ECM scaffold materials and synthetic polymers are printable and biologically active. Cartilage, bone and skin bioprinted tissues have already gone through preclinical and early clinical trials.

The other exciting field is modular tissue biofabrication where small vascularized tissue building blocks are stacked to create larger constructs. This modular technique is anticipated to resolve the existing size and vascularization constraints.

5. Needing to Cross the Vascularization Challenge.

One of the major limitations of TE is still insufficient vascularization. The engineered tissues will fail because of necrosis and dismal integration without proper supply of blood. Contemporary approaches to deal with this involve prevascularizing constructs with endothelial cells, incorporation of angiogenic factors into scaffolds, and incorporation of sacrificial inks to form pore-like channels within which host vessels merge. Microfluidic bioreactors are also vital in the preservation of perfusion in the in vitro maturation.

Innervation is also important, especially in musculoskeletal and neural tissue engineering. Tight alignment between the vascular and neural space is becoming an important procedure of graft functioning.

6. Immunomodulation and Host Response.

The immune system has two functions in the process of tissue regeneration. Although hyper-immune activation causes graft rejection, immunophilated control can be effective in improved tissue incorporation. The contemporary scaffolds are intended to induce immune cells to assume pro-generative phenotypes. Biomaterials that are cytokine-tuned and MSC-secretomes are under development to reduce fibrosis and chronic inflammation to enhance long-term graft stability.

7. The organoids and In Vitro Models.

The organoids and organ-on-chip devices are changing the paradigm of TE strategies development and validation. These cultures recreate the physiology of the human tissues in vitro enabling more exact preclinical assays and eliminating the use of animals. Scaffolds that are organoid-integrated allow the prospects of functional tissue regeneration but challenging are these types of scaffolds increased to clinically relevant sizes.

8. Production, Scale-Up, and Quality Inspections.

TE products must be translated bench to bedside using well-developed manufacturing pipelines. There is the need to have Good Manufacturing Practice (GMP) environments, closed-system bioreactors and uniform quality control procedures. The manufacturing processes already undergo automation and AI-supported monitoring to make the processes reproducible, cost-efficient, and development timelines shorter.

9. Clinical Translation/Regulatory issues.

In some countries, there are already regulatory approvals in some TE-based products such as skin substitutes, cartilage implants, etc. Nevertheless, most TE strategies remain at preclinical or early clinical stages. The regulatory challenges are caused by the hybridism of TE products whereby cells, biomaterials, and bioactive molecules are often combined. Fast-tracked regulations, responsive trial designs, and international standardization can play a very crucial role in hastening the process of clinical adoption.

10. Ethical, Safety and Commercialization.

With future advancements of TE approaches, ethical and safety issues are becoming increasingly visible-especially regarding the utilization of stem cells, exosome manipulation, and organoid models. General patient safety, achieved by long-term monitoring, post-market surveillance, and ethical control, shall be crucial. The challenges that commercialization is exposed to are also high with high production expenses, unpredictable reimbursement models, and intellectual property complexities.

11. Possible Future in Tissue Engineering.

In the next 10 years, there should be significant advances in TE.

- It is likely that modular vascularized units will be used in the future to make larger and functional tissues.
- Exosome-based and cell-free therapies can minimize regulatory challenges and the cost of productions.
- Biomaterials which are immune instructive will enhance graft integration and decrease rejection rates.
- Manufacturing of complex tissues will be able to be done in large numbers on automation platforms.
- Harmonization of regulations will assist in introducing more TE products into the clinical practice.
- With a combination of such approaches, TE can potentially solve organ shortages, enhance patient outcomes and transform regenerative medicine.

12. CONCLUSION

Tissue engineering is now a multidisciplinary career that has a major clinical prospect of success. The significant progress in biomaterials, stem cell biology, exosome biology, 3D bioprinting, and immune modulation have brought the discipline one step closer to producing functional, transplantable tissue. Nevertheless, to achieve its potential, TE has to deal with the challenges of vascularization, complexity of manufacturing, uncertainty regarding the regulations, and ethical issues. It will be necessary that a collaborative model with scientists, clinicians, regulatory agencies and industry stakeholders be employed to translate these scientific breakthroughs into actual therapies.

REFERENCES

- ✓ Ajwad N. The recent applications of stem cell-derived exosomes in regenerative medicine. Regener Med Rev 2025; 14(2):112–28.
- ✓ Chen S. Vascularization and innervation for bone tissue engineering. Bone Res Adv 2024; 9(3):245–60.

- ✓ da Silva RGL. Organizational aspects of tissue engineering clinical translation. Tissue Eng Regen Med 2024; 18(2):103–19.
- ✓ Durkin N. Clinical translation of tissue-engineered oesophageal grafts. Front Surg 2024; 11(1):87–98.
- ✓ Fan MH. Hydrogel-exosome systems in tissue engineering. Adv Drug Deliv Rev 2024; 201(5):223–40.
- ✓ Ganesan O. A review of regenerative medicine and tissue engineering. Int J Biomed Eng 2025; 7(1):55–74.
- ✓ Ghosh I. Vascular system tissue engineering: A comprehensive review. Bioeng Rep 2024; 15(2):140–57.
- ✓ Guida L. Advancements in high-resolution 3D bioprinting. J Bioprint Sci 2024; 5(2):77–93.
- ✓ Hussen BM. Recent developments and future prospects in stem-cell therapy. Stem Cell Ther 2024; 13(4):354–71.
- ✓ Hwang HS. Exosome-integrated hydrogels for bone tissue engineering. Acta Biomater 2024; 156(1):92–106.
- ✓ Iqbal MZ. Vascularization strategies in tissue engineering. Tissue Cell 2024; 82(5):102–19.
- ✓ Khan AR. Progress in 3D-printed hybrid bone scaffolds. J Orthop Bioeng 2024; 21(2):143–60.
- ✓ Kim YH. Biomaterials and scaffolds for tissue engineering. Mater Med 2024; 45(3):301–22.
- ✓ Lele M. Global trends in clinical trials involving engineered tissues. Clin Trials Regen Med 2024; 11(2):176–90.
- ✓ Li L. Engineering exosomes and nanovesicles for tissue repair. NanoBioTech J 2024; 19(1):58–74.
- ✓ Lv N. Research progress of vascularization strategies in tissue engineering. Tissue Eng Rev 2024; 18(1):97–114.
- ✓ Meretsky CR. Advances in tissue engineering and its future. Annu Rev Biomed Eng 2024; 26(2):207–30.
- ✓ Mirsky NA. Three-dimensional bioprinting: A comprehensive review. 3D Print Addit Manuf 2024; 11(3):167–82.
- ✓ Muniz TDPTP. Mesenchymal stem cells and tissue bioengineering. Stem Cell Biol J 2024; 9(2):180–95.
- ✓ Norouzi S. Recent advances in biomaterials for tissue engineering. Mater Sci Eng C 2024; 150(4):112–29.
- ✓ Park S. Fostering tissue engineering and regenerative medicine. J Regen Innov 2024; 17(1):23–41.
- ✓ Sleem B. From bone to blood flow: Tissue engineering in orthopedics. Orthop Regen Med J 2025; 12(2):200–20.
- ✓ Sun Y. Therapeutic applications of mesenchymal stem cell-derived products. Ther Adv Regen 2024; 9(1):45–63.
- ✓ Synofzik J. Ink-structing the future of vascular tissue engineering. Adv Biofabrication 2024; 6(2):190–208.
- ✓ Vargas-Ovalle MI. Plant-based scaffolds for tissue engineering: A review. Green Biomater 2025; 4(1):88–103.
- ✓ Wang Z. Advances in 3D printing technology for bone tissue engineering. Bone Joint Biomater 2024; 10(3):150–66.
- ✓ Zoghi S. A review of bioprinting techniques, scaffolds, and bioinks. Bioprint Biofabrication J 2024; 14(2):125–42.